These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 34448849)

  • 1. Aspirin for the primary prevention of cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis.
    Pallikadavath S; Ashton L; Brunskill NJ; Burton JO; Gray LJ; Major RW
    Eur J Prev Cardiol; 2022 Feb; 28(17):1953-1960. PubMed ID: 34448849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aspirin to target arterial events in chronic kidney disease (ATTACK): study protocol for a multicentre, prospective, randomised, open-label, blinded endpoint, parallel group trial of low-dose aspirin vs. standard care for the primary prevention of cardiovascular disease in people with chronic kidney disease.
    Gallagher H; Dumbleton J; Maishman T; Whitehead A; Moore MV; Fuat A; Fitzmaurice D; Henderson RA; Lord J; Griffith KE; Stevens P; Taal MW; Stevenson D; Fraser SD; Lown M; Hawkey CJ; Roderick PJ
    Trials; 2022 Apr; 23(1):331. PubMed ID: 35449015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aspirin for prophylactic use in the primary prevention of cardiovascular disease and cancer: a systematic review and overview of reviews.
    Sutcliffe P; Connock M; Gurung T; Freeman K; Johnson S; Kandala NB; Grove A; Gurung B; Morrow S; Clarke A
    Health Technol Assess; 2013 Sep; 17(43):1-253. PubMed ID: 24074752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aspirin and cardiovascular primary prevention in non-endstage chronic kidney disease: A meta-analysis.
    Major RW; Oozeerally I; Dawson S; Riddleston H; Gray LJ; Brunskill NJ
    Atherosclerosis; 2016 Aug; 251():177-182. PubMed ID: 27341534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aspirin for Primary Prevention of Cardiovascular Disease and Renal Disease Progression in Chronic Kidney Disease Patients: a Multicenter Randomized Clinical Trial (AASER Study).
    Goicoechea M; de Vinuesa SG; Quiroga B; Verde E; Bernis C; Morales E; Fernández-Juárez G; de Sequera P; Verdalles U; Delgado R; Torres A; Arroyo D; Abad S; Ortiz A; Luño J
    Cardiovasc Drugs Ther; 2018 Jun; 32(3):255-263. PubMed ID: 29943364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aspirin has potential benefits for primary prevention of cardiovascular outcomes in diabetes: updated literature-based and individual participant data meta-analyses of randomized controlled trials.
    Seidu S; Kunutsor SK; Sesso HD; Gaziano JM; Buring JE; Roncaglioni MC; Khunti K
    Cardiovasc Diabetol; 2019 Jun; 18(1):70. PubMed ID: 31159806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials.
    Sanmuganathan PS; Ghahramani P; Jackson PR; Wallis EJ; Ramsay LE
    Heart; 2001 Mar; 85(3):265-71. PubMed ID: 11179262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is there a cardiovascular protective effect of aspirin in chronic kidney disease patients? A systematic review and meta-analysis.
    Qu B; He Y; Wu L; Lu H; Wu H; Li M
    Int Urol Nephrol; 2020 Feb; 52(2):315-324. PubMed ID: 31820360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Aspirin Use for Primary Prevention With Cardiovascular Events and Bleeding Events: A Systematic Review and Meta-analysis.
    Zheng SL; Roddick AJ
    JAMA; 2019 Jan; 321(3):277-287. PubMed ID: 30667501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular events.
    Squizzato A; Bellesini M; Takeda A; Middeldorp S; Donadini MP
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD005158. PubMed ID: 29240976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-dose aspirin for prevention of cardiovascular disease in patients with chronic kidney disease.
    Kim AJ; Lim HJ; Ro H; Ko KP; Han SY; Chang JH; Lee HH; Chung W; Jung JY
    PLoS One; 2014; 9(8):e104179. PubMed ID: 25093403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aspirin Efficacy in Primary Prevention: A Meta-analysis of Randomized Controlled Trials.
    Barbarawi M; Kheiri B; Zayed Y; Gakhal I; Al-Abdouh A; Barbarawi O; Rashdan L; Rizk F; Bachuwa G; Alkotob ML
    High Blood Press Cardiovasc Prev; 2019 Aug; 26(4):283-291. PubMed ID: 31280451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aspirin effect on the incidence of major adverse cardiovascular events in patients with diabetes mellitus: a systematic review and meta-analysis.
    Butalia S; Leung AA; Ghali WA; Rabi DM
    Cardiovasc Diabetol; 2011 Apr; 10():25. PubMed ID: 21453547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aspirin for Primary Prevention of Cardiovascular Events.
    Abdelaziz HK; Saad M; Pothineni NVK; Megaly M; Potluri R; Saleh M; Kon DLC; Roberts DH; Bhatt DL; Aronow HD; Abbott JD; Mehta JL
    J Am Coll Cardiol; 2019 Jun; 73(23):2915-2929. PubMed ID: 31196447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis.
    Palmer SC; Navaneethan SD; Craig JC; Johnson DW; Perkovic V; Hegbrant J; Strippoli GF
    Cochrane Database Syst Rev; 2014 May; (5):CD007784. PubMed ID: 24880031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aspirin for Primary and Secondary Prevention of Mortality, Cardiovascular Disease, and Kidney Failure in the Chronic Renal Insufficiency Cohort (CRIC) Study.
    Taliercio JJ; Nakhoul G; Mehdi A; Yang W; Sha D; Schold JD; Kasner S; Weir M; Hassanein M; Navaneethan SD; Krishnan G; Kanthety R; Go AS; Deo R; Lora CM; Jaar BG; Chen TK; Chen J; He J; Rahman M;
    Kidney Med; 2022 Nov; 4(11):100547. PubMed ID: 36339663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force.
    Wolff T; Miller T; Ko S
    Ann Intern Med; 2009 Mar; 150(6):405-10. PubMed ID: 19293073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bleeding Risks With Aspirin Use for Primary Prevention in Adults: A Systematic Review for the U.S. Preventive Services Task Force.
    Whitlock EP; Burda BU; Williams SB; Guirguis-Blake JM; Evans CV
    Ann Intern Med; 2016 Jun; 164(12):826-35. PubMed ID: 27064261
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.